BioSpace News Archive

For the first time, scientists have linked memory impairment in mammals with the expression of endogenous retroviruses (ERVs) within an organism’s genome.

C2N Diagnostics today announced that it will present data from a proof-of-concept study of its APTUS™-Aβ blood test on Friday December 6th at 5 PM at the Late Breaking session of Clinical Trials in Alzheimer’s Disease 2019 conference (Hilton Bayfront in San Diego, CA)

Paratek Pharmaceuticals, Inc. announced that on November 29, 2019, the Company granted stock options and restricted stock units to one new employee of the Company.

Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that it has granted non-statutory stock options to purchase an aggregate of 18,000 ordinary shares of Nabriva Therapeutics as inducements to 4 newly-hired employees.

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced today that the Company will present at the following conferences in December:

Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI), an international leader in sustainable bioprotection and plant health solutions, announced today that company founder Dr. Pamela Marrone will retire from her position as chief executive officer

Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that JAMA Neurology has published the results of Zogenix’s Phase 3 study (Study 1504) of the investigational drug, FINTEPLA® (ZX008, fenfluramine oral solution

Amgen (NASDAQ:AMGN) today announced new clinical data from its oncology in-line products and pipeline that will be presented at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Dec. 7-10, 2019.

Richard Marizan joins Amatus Health as the Vice President of Revenue Cycles.

ViewRay, Inc. (Nasdaq: VRAY) announced today that it has signed a non-binding memorandum of understanding for collaboration with Elekta AB (Nasdaq: EKTA-B.ST) (“Elekta”) to advance the knowledge and use of MR-guided radiation therapy. In connection with the collaboration, Elekta has committed to invest capital for up to a 9.9% minority interest in ViewRay